Lipoprotein (a) [Lp(a)] is a risk factor for coronary artery disease. It is characterized by apolipoprotein (a) [apo(a)] disulphide linked to apolipoprotein B (apoB), by Cys4057 of apo(a) and possibly Cys3734 of apoB. We call this the covalent apo(a):apoB-Lp interaction, to distinguish it from the noncovalent Lp(a):apoB-Lp interaction, mediated by the prolinebinding kringle-4-like domain(s) of Lp(a). The Lp(a):apoB-Lp interaction was inhibited by an apoB peptide spanning residues 3304-3317. This peptide was found by a computerized search for sites on apoB similar to the plasminogen's kringle-4-binding site of a2-antiplasmin. It probably constitutes part of the Lp(a)-
INTRODUCTION
Lipoprotein (a) [Lp(a)] is a risk factor for coronary artery disease [1] [2] [3] . It is a low-density lipoprotein (LDL) particle with a distinguishing glycoprotein, apolipoprotein (a) [apo(a)], covalently linked to apolipoprotein B (apoB) by a disulphide bond [4] . Apo(a) is highly homologous to plasminogen and its gene possibly arose by duplication of the plasminogen gene [5] . It has many repeats of kringle-4-like domains, one kringle-5-like domain, and a domain analogous to the protease domain of plasminogen but lacking the activation site [5] . Lp(a) assembly is mediated by Cys4057 of apo(a)'s kringle-36 and possibly Cys3734 of apoB [6] [7] [8] . We call this the covalent apo(a):apoB-Lp interaction, to distinguish it from the non-covalent Lp(a): apoB-Lp interaction which is the topic of this paper. ApoB-Lp is defined as apoB-containing lipoprotein, exclusive of Lp(a).
The Lp(a): apoB-Lp interaction was initially demonstrated by affinity chromatography, affinity electrophoresis and ligand blotting [9] . When Lp(a) and LDL are mixed together, they form an Lp(a): LDL complex which has an intermediate mobility between Lp(a) and LDL on agarose gel electrophoresis [9] . Lp(a), immobilized on nitrocellulose membrane or coupled to Sepharose-6B, binds apoB-Lp [9] . The nitrocellulose membrane system was exploited to quantify the Lp(a): apoB-Lp interaction [10] . The interaction exhibits a binding constant of 2 x 10-8 M and a stoichiometry of two apoB-Lp/one Lp(a) [10] .
The kringle-4-like domain(s) of Lp(a) is responsible for the binding of Lp(a) to apoB-Lp as a synthetic kringle peptide inhibits the binding of apoB-Lp to Lp(a) (KI = 1.9 X 10-4 M) [11] . In comparison with plasminogen kringle-4, the aspartic acid residue critical for lysine binding is replaced by valine in most of Lp(a)'s kringle-4-like domains, conferring affinity to L-proline rather than L-lysine [1 1 ]. An analogue of lysine, 6-aminohexanoic binding site on apoB because: (1) it corresponds to the x2-antiplasmin minimum binding domain for plasminogen's kringle-4; (2) the competitive nature of inhibition [KI = (1.5 + 0.7) x 10-4 M, n = 5] suggested that it and apoB-Lp bound to Lp(a) by the same mechanism at the same site; and (3) it specifically bound Lp(a) and not apoB-Lp, and the bound Lp(a) was dissociated by inhibitors of the Lp(a): apoB-Lp interaction, 6-aminohexanoic acid and L-proline. Inhibition was independent of its proline residue, suggesting that proline in the context of a peptide is not a ligand for the kringle(s) which mediated the binding of Lp(a) to apoB-Lp.
acid, can adopt a conformation similar to that of L-proline and can also inhibit the binding of apoB-Lp to Lp(a) [11] .
The Lp(a): apoB-Lp interaction has also been observed in other systems. Immunoprecipitation by anti-apo(a) brought down both Lp(a) and apoB-Lp non-covalently associated with Lp(a) [12] . The accumulation of Lp(a), in the triacylglycerol-rich apoB-Lp fraction of hypertriacylglycerolaemic patients, is mimicked by the addition of purified Lp(a) to the affected plasma due to the binding of Lp(a) to the triacylglycerol-rich apoB-Lp [10, 13, 14] . Lp(a), bound or immobilized on LDL-receptornegative fibroblasts, mediates the binding of additional apoBLp; the effect is inhibited by L-proline [15] . Similarly, Lp(a), bound or immobilized on HepG2 cells, causes a greater than 2-fold increase in LDL binding [16] .
In this paper, we report our studies of an apoB peptide which inhibits the Lp(a): apoB-Lp interaction. This peptide was found during a computerized search for an apoB equivalent to the a2-antiplasmin-binding domain for plasminogen's kringle- 4 I To whom correspondence and reprint requests should be addressed. 17 sheets from BioTrace NT, Gelman Sciences, Ann Arbor, MI, U.S.A. All other chemicals were of reagent grade.
Bestflt search Bestfits were found using the local homology algorithm of Smith and Waterman [17] with gap weight of 3.0 and length weight of 0.10. The apoB sequence was broken down into eight 500-aminoacid blocks for the search as the GCG program from the Wisconsin Genetic Group is not capable of handling longer sequences effectively.
Lipoprotein Isolation
Human plasma samples obtained from a local blood bank were collected by plasmapheresis from healthy subjects. To prevent degradation by proteolytic enzymes, the plasma was adjusted with PPACK, leupeptin, NaN3, and phenylmethanesulphonyl fluoride to final concentrations of 1 ,uM, 40 jug/ml, 0.1 % and 0.5 ,uM, respectively [9] . LDL2 (p = 1.030-1.063 g/ml) and Lp(a) from high-density lipoprotein (HDL)2 (p = 1.063-1.12 g/ml) were isolated by sequential ultracentrifugation and column chromatography as previously described [9] . Homogeneity of Lp(a) was assessed by non-denaturing gradient gel electrophoresis (GGE) combined with immunoblotting for Lp(a) and LpB.
Recombinant apo(a) containing 17 kringle-4-like domains plus the kringle-5 and protease domains purified by lysineSepharose chromatography from the conditioned media of transfected human 293 cells [12] was obtained from Dr. Richard Lawn at Stanford University, Palo Alto, CA, U.S.A.
Peptide synthesis
Synthetic peptides were synthesized on an Applied Biosystem synthesizer (model 430A), purified by h.p.l.c., and characterized by amino acid analysis as described [18] at the Molecular Biology Resource Facility, Oklahoma University Health Sciences Center or in the Wallenberg Laboratory using Milligen peptide synthesizers (Model 9050) according to Sheppard [19] , University of G6teborg, G6teborg, Sweden. All synthetic peptides exhibited a single peak on h.p.l.c. and the predicted amino acid composition. The di-and tri-peptides were obtained from Bachem Bioscience Inc., King of Prussia, PA, U.S.A.
Peptide-Sepharose column chromatography Synthetic apoB3304-3317 peptide (300 mg) was suspended in 50 ml of 0.2 M borate buffer, pH 8.5, and allowed to react with 7 g of CNBr-activated Sepharose 4B (Pharmacia, Sweden) according to the manufacturer's instructions. By protein determination, 96 % of the peptide was attached to the column. The final bed volume of 40 ml yielded a minimum covalently attached peptide concentration of 4.5 x 10-3 M. The peptide column was poured as previously described for immunosorbers [20] . Three Lp(a)-positive and three Lp(a)-negative plasma samples were passed separately over the column after it was equilibrated in 0.05 M Tris/HCl, pH 7.5, 0.15 M NaCl, 0.02% EDTA and the unretained fraction eluted in the same buffer. The retained proteins were dissociated from the column with 0.1 M 6-aminohexanoic acid or 0.1 M L-proline, followed by 3 M NaSCN as previously described. The elution pattern was very similar to the pattern from immunosorbers [20] ; and each retained fraction was collected and concentrated by dialysis against PEG-18000.
Plasma from random normolipidaemic individuals were classified as Lp(a)-positive or Lp(a)-negative by double diffusion analysis using polyclonal anti-Lp(a). We have shown previously that this yielded a detection level for Lp(a)-positive plasma of > 9 mg/dl and < 9 mg/dl for Lp(a)-negative plasma [21] . The plasma apoB concentration is 96 + 24 mg/dl and plasma Lp(a) concentration is 18.6 + 17.9 mg/dl [22] . The Lp(a) and LDL mixture had 34 mg/dl of Lp(a) and 800 mg/dl of LDL. To avoid exceeding the binding capacity of the column, we only used 2 ml of plasma and only 1 ml of the mixture.
Electrophoretic analyses SDS/gradient polyacrylamide gel electrophoresis (SDS/PAGE; 2.5-10 %), non-denaturing polyacrylamide gradient gel electrophoresis (GGE; 1.5-15 %), and immunoblotting were performed as previously described [11] . In some experiments, alkaline phosphatase-conjugated antibody was used and blots visualized using the phosphatase substrate from Kirkegaard and Perry Laboratories Inc., Gaithersburg, MD, U.S.A.
Ilgand dot blotting Ligand dot blotting was performed as previously described [10] using Bio-Trace nitrocellulose membrane (Gelman Sciences, Ann Arbor, MI, U.S.A.), 3,3-diaminobenzidine tetrahydrochloride tablets (Ken En Tec, Copenhagen, Denmark) as visualizing agent, and a dot blot apparatus (S & S, Keene, NH, U.S.A.). In some experiments, the intensity was determined using the Optimas system from BioScan Inc., Edmonds, WA, U.S.A. LDL2 was biotinylated by reaction of a 1 mg/ml solution of purified lipoproteins in 0.2 M borate buffer, pH 8.5, with 60 ,tl/ml of freshly made Biotin-X-NHS (Boehringer Mannheim), 1.2 mg/ml in dimethyl sulphoxide as described [9] .
Other methods Double diffusion was performed using monospecific antisera as described previously using 1 % agar in Veronal buffer [11] . Protein determination was performed using the Bio-Rad dye reagent (Richmond, CA, U.S.A. 
RESULTS
Inhibition of Lp(a): apoB-Lp interaction by apoB3" '317 peptide
The T-1l tryptic peptide (G427DKLFGPDLKLVPPMEEDY-PQFGSPK452) ofa2-antiplasmin has an affinity for plasminogen's kringle-4 with a KD of 0.7-29 1tM; the right half of which is the minimum binding site and has a KD of 250 uM [23] . The human apoB amino acid sequence was searched for sequences similar to the T-1I sequence. The results are shown in Figures 1 and 2 . The two sites shown in Figure 2 were chosen for further analyses, since they have the highest similarity to the T-l sequence. Site 1 (residues 3284-3318) and site 2 (residues 3700-3733) exhibit 76% and 65 % sequence similarity to the T-1 sequence respectively ( Figure 2 ). Alignment at site 1 and site 2 forced a gap which breaks the T-l sequence into half, the right half corresponds to its minimum binding site.
Synthetic peptides spanning residues 3285-3296 (B1), 3304-3317 (B2), 3700-3711 (B3), and 3719-3733 (B4), were tested for inhibition of the Lp(a): apoB-Lp interaction. As shown in Figure  2 , peptide B2 (apoB3304-3317) completely inhibited the binding of biotinylated LDL2 to immobilized Lp(a). The apoB3304-3317 peptide also inhibited the binding of LDL2 to recombinant apo(a) (data not shown). These data suggested that site 1 is the Lp(a)-binding site on apoB. This interpretation is consistent with the competitive nature of inhibition by the apoB33043317 peptide. In the presence of increasing amounts of apoB3304-3317 peptide, the apparent KD decreased while maximum binding (Bmax ) was not affected (Figure 3) . The KI was determined to be (1.5+0.7)x10-4M of apoB3304-3317 peptide (n = 5). KI was determined graphically by plotting the apparent KD values versus the inhibitor concentrations; the x-axis intercept is equal to -KI (Figure 3 apoB3304-3317-Sepharose column, Lp(a) was bound and was eluted with 0.1 M 6-aminohexanoic acid (Figure 4) . This was the case with or without prior passage over L-lysine-Sepharose to remove proteins with affinity for amino acids [especially L-lysine which also has an affinity for Lp(a)]. The double immunodiffusion reactions to apo(a) and apoB of all 6-aminohexanoic acid fractions exhibited a line of identity, indicating that apo(a) and apoB reside on the same particle, i.e. Lp(a) (Figures 4b and 4c) . And upon immunoblotting, Lp(a)-positive plasma exhibited two apoB reactivities corresponding to apoB and apoB linked to apo(a) ( Figure 5, lane 1) ; while the 6-aminohexanoic acid eluate exhibited primarily one reactivity corresponding to apoB linked to apo(a) ( Figure 5, lanes 3 and 4) . This showed that only Lp(a), and not apoB-Lp, was bound by the column. Little or no Lp(a) remained after 6-aminohexanoic acid elution, as no Lp(a) was detected with the subsequent 3 M NaSCN wash ( Figure 5, lane  2) .
The binding of Lp(a) to the column was specific because of four facts. First, Lp(a) did not bind to a column constructed Table I inhibition of binding by various peptides  B2 and its variants Lp(a):apoB-Lp interaction, was also less effective in eluting Lp(a) from the apoB 3304-3317 column (results not shown). Thirdly, no other apolipoproteins, including apoB-Lp, were bound to the column, as determined by double immunodiffusion analyses (Figures 4a and 4b ) or immunoblotting ( Figure 5 ). Fourthly, binding was independent of other plasma proteins as only Lp(a) was bound when a mixture of purified LDL and Lp(a) was passed over the column (Figure 4c ). However, like lysine and plasminogen [24] , inhibition by free proline was characterized by stereospecificity; L-proline was more effective than D-proline ( Figure 6 ). Furthermore, the KI of L-proline for Lp(a) (Figure 6 ) is equivalent to the KI of L-lysine for plasminogen [25] (30 mM versus 25-27 mM). Thus free Lproline is probably a ligand for the kringle(s) which mediates the binding of Lp(a) to apoB-Lp.
DISCUSSION
We have shown that the binding of Lp(a) to apoB-Lp is inhibited by an apoB peptide spanning residues 3304-3317. It is likely that this peptide is part of the Lp(a)-binding site on apoB for three reasons. First, the peptide corresponds to the a2-antiplasmin minimum binding domain for plasminogen's kringle-4 which is highly homologous to Lp(a)'s kringle-4-like domains. Secondly, the competitive nature of inhibition suggested that the peptide and apoB-Lp bound to Lp(a) by the same mechanism at the same site(s). Thirdly, the peptide specifically bound Lp(a) and not apoB-Lp; and the bound Lp(a) was dissociated by inhibitors of the Lp(a): apoB-Lp interaction, i.e. 6-aminohexanoic acid and Lproline.
The Lp(a): apoB-Lp interaction is both hydrophobic and ionic; however, the hydrophobic forces predominated because the interaction is demonstrable at a high salt concentration (> 2 M NaCl), while no interaction is demonstrable at low salt concentration (<0.08 M NaCl). Therefore, the binding site for Lp(a) was predicted to be an exposed hydrophobic domain on apoB [10] . Site 1 is probably hydrophobic and exposed on the basis of its theoretical hydrophobicity index and antigenicity index. In contrast, site 2 may not be exposed based on its low antigenicity index. Close to site 1 are three glycosylation sites (residues 3309, 3331, and 3384) [26] . Glycosylation should insure the surface exposure of site 1 and might contribute sterically to the binding reaction. In this regard, it has been shown by protease digestion, using 12 different proteases, that there is only one highly exposed region in LDL and very-low-density lipoproteins (VLDL) (residues 3180-3280) [27] . Site 1 is in close proximity to this exposed region and should be available for the binding between apoB-100 of both VLDL and LDL to Lp(a) as shown previously [28] . Therefore, site 1 is probably the Lp(a)-binding site on apoB. The fact that site 2, which corresponds to the apoB domain involved in the covalent apo(a):apoB-Lp interaction, was also detected by the computerized search suggested that this apo(a):apoB-Lp interaction could also be analogous to the plasminogen: a2-antiplasmin interaction.
Despite the fact that site 1 was found using the a2-antiplasmin minimum binding site for plasminogen kringle-4, we would like to point out that site 1 is similar to, but not the same as, the T-11 peptide of a2-antiplasmin, as reflected in the low degree of similarity between the two domains. Purified a2-antiplasmin was not able to inhibit the binding of LDL to immobilized Lp(a) even when added at a concentration of 0.5 mg/ml (7.6 x 10-6 M). Furthermore, apoB-Lp binding to Lp(a) is lipid dependent, delipidized apoB refolded according to the method of Kamanna et al. [29] did not bind to Lp(a) (V. N. Trieu, unpublished work); and a2-antiplasmin binding to plasminogen is not lipid dependent.
The apoB3304-3317 column has allowed us to remove Lp(a) from the plasma compartment rapidly and efficiently. The minimum peptide concentration of this column is 4.5 x 10-3 M which is 30 times the KI of the peptide and 5 times the concentration of the peptide which completely inhibited apoB-Lp binding to Lp(a) at any apoB-Lp concentrations. Therefore, it is not unexpected that the presence of apoB-Lp in the plasma. This observation offers an opportunity to develop a new and rapid Lp(a) assay, i.e. Lp(a) from plasma could be immobilized on to a peptide-containing support and its cholesterol determined directly or after dissociation of Lp(a) from the matrix.
The formation of Lp(a):apoB-Lp complex could be of importance physiologically. It has been shown to result in the enhancement of apoB-Lp binding to LDL-receptor-negative fibroblasts and enhanced uptake of both Lp(a) and LDL in LDL-receptor-positive HepG2 cells [15, 16] . The piggybacking effect of Lp(a) could explain why Lp(a) was catabolized more rapidly in transgenic mice overexpressing LDL receptor although it has little affinity for LDL receptor [30] . As there is also a distinct receptor on macrophages [31, 32] , the binding of Lp(a) to apoB-Lp should result in a similar enhancement of apoB-Lp uptake and therefore foam-cell formation which is the first step in atherosclerosis. Furthermore, as Lp(a) has an affinity for both the extracellular matrix and apoB, it could enhance the binding of apoB to the vascular wall. Normal cellular responses to the bound LDL could result in the formation of atherosclerotic lesions.
